2013 PUBLICATIONS


Hohl RJ. Personalized Medicine: Through the looking glass of functional imaging. Clin Cancer Res 19(15):4024-26, 2013. PMID: 23785049

Tong H, Kuder CH, Wasko BM, Hohl RJ.  Quantitative determination of isopentenyl diphosphate in cultured mammalian cells.  Anal Biochem 43(1):36-42, 2013.  PMID: 23000003

 

2012 PUBLICATIONS


Holstein SA, Hohl RJ.  Is there a future for prenyltransferase inhibitors in cancer therapy?  Curr Opin Pharmacol 12:704-709, 2012.  PMID: 22817869

Kuder CH, Sheehy RM, Neighbors JD, Wiemer DF, Hohl RJ.  Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification.  Mol Pharmacol 82(1):9-16, 2012.  PMID: 22461663

Holstein SA, Hohl RJ.  Therapeutic additions and possible deletions in oncology in 2011.  Clin Pharmacol Ther (Review) 91(1):15-17, 2012.  PMID: 22179625

Weivoda MM, Hohl RJ.  Geranylgeranyl pyrophosphate stimulates PPARy expression and adipogenesis through the inhibition of osteoblast differentiation.  Bone 50(2):467-476, 2012.  PMID: 22019459

Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Pérez I, Nieto A, Tercero JC, Alfaro V, Tamborini E, Blay JY.  Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.  Ann Oncol 23(3):771-776, 2012.  PMID: 21642514

 

2011 PUBLICATIONS


Wiemer AJ, Wiemer DF, Hohl RJ.  Geranylgeranyl diphosphate synthase: an emerging therapeutic target.  Clin Pharmacol Ther (Review) 90(6):804-812, 2011.  PMID: 22048229

Wasko BM, Smits JP, Shull LW, Wiemer DF, Hohl RJ.  A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.  J Lipid Res 52(11):1957-1964, 2011.  PMID: 21903868

Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A.  Clinical pharmacology as a foundation for translational science.  Clin Pharmacol Ther 90(1):10-13, 2011.  PMID: 21691266

Holstein SA, Kuder CH, Tong H, Hohl RJ.  Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis.  Lipids 46(10):907-921, 2011.  PMID: 21633866

Weivoda MM, Hohl RJ.  Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation.  Endocrinology 152(8):3113-3122, 2011.  PMID: 21586555

Wasko BM, Dudakovic A, Hohl RJ.  Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.  J Pharmacol Exp Ther 337(2):540-546, 2011.  PMID: 21335425

Holstein SA, Hohl RJ.  Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.  Leuk Res 35(4):551-559, 2011.  PMID: 20828814

Dudakovic A, Tong H, Hohl RJ.  Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration.  Invest New Drugs 29(5):912-920, 2011.  PMID: 20480384

 

2010 PUBLICATIONS


Ulrich NC, Kuder CH, Hohl RJ, Wiemer DF.  Biologically active biotin derivatives of schweinfurthin F.  Bioorg Med Chem Lett 20(22):6716-6720, 2010.  PMID: 20869871

Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF.  Synthesis and biological evaluation of a series of aromatic bisphosphonates.  Bioorg Med Chem 18(20):7212-7220, 2010.  PMID: 20832326

Topczewski JJ, Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF.  Fluorescent schweinfurthin B and F analogs with anti-proliferative activity.  Bioorg Med Chem 18(18):6734-6741, 2010.  PMID: 20724169

Ulrich NC, Modet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF.  Structural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure.  Bioorg Med Chem 18(4):1676-1683, 2010.  PMID: 20116262

Holstein SA, Tong H, Hohl RJ.  Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.  Leuk Res 34(3):344-351, 2010.  PMID: 19646757

 

2009 PUBLICATIONS


Holstein SA, Tong H, Kuder CH, Hohl RJ.  Quantitative determination of geranyl diphosphate levels in cultured human cells.  Lipids 44(11):1055-1062, 2009.  PMID: 19856009

Holstein SA, Hohl RJ.  Vascular medicine:  a look forward.  Clin Pharmacol Ther 86(2):117-119, 2009.  PMID: 19621001
Wiemer AJ, Hohl RJ, Wiemer DF.  The intermediate enzymes of isoprenoid metabolism as anticancer targets.  Anticancer Agents Med Chem 9(5):526-542, 2009.  PMID: 19519294

Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF.  Synthesis and biological activity of a fluorescent schweinfurthin analogue.  Bioorg Med Chem 17(13):4718-4723, 2009.  PMID: 19464190

Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callender N, Lister J, Oken M, Jagannath S.  Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.  Leuk Lymphoma 50(4):559-565, 2009.  PMID: 19373653

Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ.  Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.  J Clin Oncol 27(11):1800-1805, 2009.  PMID: 19255312

Holstein SA, Stokes JB, Hohl RJ.  Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.  Leuk Res 33(2):344-347, 2009.  PMID: 18835038

 

2008 PUBLICATIONS


McLennan G, Clarke L, Hohl RJ.  Imaging as a biomarker for therapy response: cancer as a prototype for the creation of research resources.  Clin Pharmacol Ther 84(4):433-436, 2008.  PMID: 18802422

Tong H, Wiemer AJ, Neighbors JD, Hohl RJ.  Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue.  Anal Biochem 378(2):138-143, 2008.  PMID: 18457649

Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF.  Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.  Bioorg Med Chem 16(7):3652-3660, 2008.  PMID: 18308574

Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ.  Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma:  CALGH 90207.  Ann Oncol 19(5):946-950, 2008.  PMID: 18272914

Dudakovic A, Wiemer AJ, Lamb KM, Vonnahme LA, Dietz SE, Hohl RJ.  Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.  J Pharmacol Exp Ther 324(3):1028-1036, 2008.  PMID: 18083912

Hamadmad SN, Hohl RJ.  Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism.  J Pharmacol Exp Ther 324(3):1227-1233, 2008.  PMID: 18079357

Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF.  Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.  Bioorg Med Chem 16(1):390-399, 2008.  PMID: 17905588

 

2007 PUBLICATIONS


Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ.  Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction:  CALGB 60101.  J Clin Oncol 25(21):3055-3060, 2007.  PMID: 17634483

Hamadmad SN, Hohl RJ.  Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.  Biochem Pharmacol 74(4):590-600, 2007.  PMID: 17586475

Hohl RJ.  Clinical pharmacology: bridging discovery and practice.  Clin Pharmacol Ther 81(6):783-785, 2007.  PMID: 1750548

Xing D, Murry DJ, Schmidt MS, Hohl RJ, Martins JB.  Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity.  Heart Rhythm 4(5):629-637, 2007.  PMID: 17467633

Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P.  Change in erythropoietin pharmacokinetics following hematopoietic transplantation.  Clin Pharmacol Ther 81(6):873-879, 2007.  PMID: 17429351

Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, Wiemer DF.  Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation.  Bioorg Med Chem 15(5):1959-1966, 2007.  PMID: 17254791

Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF.  Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series.  Bioorg Med Chem Lett 17(4):911-915, 2007.  PMID: 17236766

Wiemer AJ, Tong H, Swanson KM, Hohl RJ.  Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.  Biochem Biophys Res Commun 353(4):921-925, 2007.  PMID: 17208200

Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ.  Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies.  Erratum in Cancer Chemother Pharmacol 59(4):559, 2007.  PMID: 16133537

 

2006 PUBLICATIONS


Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF.  Synthesis and biological activity of isoprenoid bisphosphonates.  Bioorg Med Chem 14(12):4130-4136, 2006.  PMID: 16517172

Swanson KM, Hohl RJ.  Anti-cancer therapy: targeting the mevalonate pathway.  Curr Cancer Drug Targets 6(1):15-37, 2006 (Review).  PMID: 16475974

Hamadmad SN, Henry MK, Hohl RJ.  Erythropoietin receptor signal transduction requires protein geranylgeranylation.  J Pharmacol Exp Ther 316(1):403-409, 2006.  PMID: 16203826

Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ.  Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies.  Cancer Chemother Pharmacol 57(2):155-164, 2006.  PMID: 16133537

 

PUBLICATIONS 2005 AND PRIOR


Murthy S, Tong H, Hohl RJ.  Regulation of fatty acid synthesis by farnesyl pyrophosphate.  J Biol Chem 280(51):41793-41804, 2005.  PMID: 16221687

Lewis KA, Holstein SA, Hohl RJ.  Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo.  Leuk Res 29(5):527-533, 2005.  PMID: 15755505

Tong H, Holstein SA, Hohl RJ.  Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells.  Anal Biochem 336(1):51-59, 2005.  PMID: 15582558

Kim M, Kleckley TS, Wiemer AJ, Holstein SA, Hohl RJ, Wiemer DF.  Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues.  J Org Chem 69(24):8186-8193, 2004.  PMID: 15549786

Holstein SA, Hohl RJ.  Isoprenoids: remarkable diversity of form and function.  Lipids 39(4):293-309, 2004.  PMID: 15357017

Henry MK, Nimbalkar D, Hohl RJ, Quelle FW.  Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells.  Exp Cell Res 299(1):257-266, 2004.  PMID: 15302592

Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett E.  Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.  Cancer 101(2):370-378, 2004.

Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.  A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.  Cancer Chemother Pharmacol 54(4):368-376, 2004.  PMID: 15205914

Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA.  Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.  Biopharm Drug Dispos 25(4):149-156, 2004.  PMID: 15108217

Ownby SE, Hohl RJ.  Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis.  Lipids 38(7):751-759, 2003.  PMID: 14506838

Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA.  A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep.  J Pharmacol Exp Ther 306(2):532-537, 2003.  PMID: 12750427

Holstein SA, Hohl RJ.  Monoterpene regulation of Ras and Ras-related protein expression.  J Lipid Res 44(6):1209-1215, 2003.  PMID: 12671036

Lee CK, de Magalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.  Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.  Bone Marrow Transplant 31(2):121-128, 2003.  PMID: 12621494

Chen X, Wiemer AJ, Hohl RJ, Wiemer DF.  Stereoselective synthesis of the 5’-hydroxy-5’-phosphonate derivatives of cytidine and cytosine arabinoside.  J Org Chem 67(26):9331-9339, 2002.  PMID: 12492335

Holstein SA, Hohl RJ.  Synergistic interaction of lovastatin and paclitaxel in human cancer cells.  Mol Cancer Ther 1(2):141-149, 2001.  PMID: 12467231

Holstein SA, Wohlford-Lenane CL, Hohl RJ.  Isoprenoids influence expression of Ras and Ras-related proteins.  Biochemistry 41(46):13698-13704, 2002.  PMID: 12427032

Lee CK, de Magalhaes-Silverman M, Hayashi M, Schlueter A, Strauss RG, Hohl RJ, Gingrich RD.  A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.  Bone Marrow Transplant 29(8):647-652, 2002.  PMID: 12180108

Lee CK, de Magalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.  Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma.  Bone Marrow Transplant 29(7):615-620, 2002.  PMID: 11979313

Ownby SE, Hohl RJ.  Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells.  Lipids 37(2):185-192, 2002.  PMID: 1190891

Kang J, Kumar V, Yang D, Chowdhury PR, Hohl RJ.  Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.  Eur J Pharm Sci 15(2):163-170, 2002.  PMID: 11849913

Holstein SA, Wohlford-Lenane CL, Hohl RJ.  Consequences of mevalonate depletion.  Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB.  J Biol Chem 277(12):10678-10682, 2002.  PMID: 11788600

Kumar V, Kang J, Hohl RJ.  Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying.  Pharm Dev Technol 6(3):459-467, 2001.  PMID: 11485187

Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA.  Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.  J Pharmacol Exp Ther 298(2):820-824, 2001.  PMID: 11454947

Holstein SA, Hohl RJ.  Interaction of cytosine arabinoside and lovastatin in human leukemia cells.  Leuk Res 25(8):651-660, 2001.  PMID: 11397469

Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.  Blood 97(11):3361-3369, 2001.  PMID: 11369625

Cermak DM, Wiemer DF, Lewis K, Hohl RJ.  2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization.  Bioorg Med Chem 8912):2729-2737, 2000.  PMID: 11131164

Jung KY, Hohl RJ, Wiemer AJ, Wiemer DF.  Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside.  Bioorg Med Chem 8(10):2501-2509, 2000.  PMID: 11058045

Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA.  A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse.  Br J Cancer 83(5):588-593, 2000.  PMID: 10944597

Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, Lester E, Kirshner JJ, Vinciguerra V, Paskett E.  Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473.  Clin Cancer Res 5(12):3942-3947, 1999.  PMID 10632323

Lee CK, Gingrich RD, de Magalhaes-Silverman M, Hohl RJ, Joyce JK, Scott SD, Wen BC, Schlueter A.  Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation.  Biol Blood Marrow Transplant 5(1):15-27, 1999.  PMID: 10232737

Hohl RJ, Sherburne AR, Feeley JE, Huisman TH, Burns CP.  Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin Cheverly.  Am J Hematol 59(3):181-184, 1998.  PMID 9798654

Holstein SA, Cermak DM, Wiemer DF, Lewis K, Hohl RJ.  Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase.  Bioorg Med Chem 6(6):687-694, 1998.  PMID: 9681134

Hohl RJ, Lewis KA, Cermak DM, Wiemer DF.  Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids.  Lipids 33(1):39-46, 1998.  PMID: 9470172

Lewis KA, Hohl RJ.  Modulation of RAS expression in human malignant cells by dietary supplements.  Nutrition 13(10):921-923, 1997.  PMID: 9357036

Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G.  Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras.  Blood 88(12):4611-4619, 1996.  PMID: 8977253

Peters C, Miller J, Abel SL, McMillan SK, Getchell JP, Giller RH, Hohl RJ, de Alarcon PA.  Iowa newborn hemoglobinopathy screening and comprehensive care: a model for rural states.  J Pediatr Hematol Oncol 18(4):416-418, 1996.  PMID: 8888756

Lee CK, Harman GS, Hohl RJ, Gingrich RD.  Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment.  Bone Marrow Transplant 18(3):573-577, 1996.  PMID: 8879620

Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.  Clin Cancer Res 2(3):483-491, 1996.  PMID: 981694

Hohl RJ.  Monoterpenes as regulators of malignant cell proliferation.  Adv Exp Med Biol 401:137-146, 1996.  PMID: 8886132
Clamon GH, Riggs CE Jr, Dreicer R, Hohl RJ.  Phase II trial of edatrexate in patients with metastatic colorectal cancer.  Invest New Drugs 13(4):359-361, 1996.  PMID: 8824357

Hohl RJ, Lewis K.  Differential effects of monoterpenes and lovastatin on RAS processing.  J Biol Chem 270(29:17508-17512, 1995.  PMID: 7615555

Lee CK, Gingrich RD, Hohl RJ, Ajram KA.  Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation.  Bone Marrow Transplant 16(1):175-182, 1995.  PMID: 7581119

Hohl RJ, Kennedy EJ, Frischer H.  Defenses against oxidation in human erythrocytes: role of glutathione reductase in the activation of glucose decarboxylation by hemolytic drugs.  J Lab Clin Med 117(4):325-331, 1991.  PMID: 1901343

Hohl RJ, Larson RA, Mannickarottu V, Yachnin S.  Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells.  Blood 77(5):1064-1070, 1991.  PMID: 1995091

Hohl RJ, Schilsky RL.  Nonmalignant complications of therapy for Hodgkin’s disease.  Hematol Oncol Clin North Am - Review 3(2):331-343, 1989.  PMID: 2663831